Influence of cytokine gene polymorphisms on erythropoetin dose requirements in chronic haemodialysis patients

Nephrology Dialysis Transplantation

Volumn 22, Issue 12, 2007, Pages 3586-3592

  Girndt, Matthias ^a   Stenvinkel, Peter ^b   Ulrich, Christof ^a   Axelsson, Jonas ^b   Nordfors, Louise ^b   Barany, Peter ^b   Carrero, Juan Jesus ^b   Heine, Gunnar H ^a   Kaul, Harald ^c   Köhler, Hans ^a  

^a SAARLAND UNIVERSITY   (Germany)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^c Klinikum Deggendorf   (Germany)

Author keywords

Cytokines; Erythropoetin; Haemodialysis; Inflammation; Kidney failure chronic; Polymorphism genetic

Indexed keywords

C REACTIVE PROTEIN; CYTOKINE; HEMOGLOBIN; INTERLEUKIN 10; INTERLEUKIN 6; IRON; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; RECOMBINANT ERYTHROPOIETIN;

ADULT; AGED; ALLELE; ARTICLE; CLINICAL TRIAL; CYTOKINE RELEASE; DNA POLYMORPHISM; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; FEMALE; GENOTYPE; HEMATOPOIESIS; HEMODIALYSIS; HEMOGLOBIN BLOOD LEVEL; HUMAN; INFLAMMATION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MULTIPLE REGRESSION; PREDICTIVE VALIDITY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL;

ADULT; AGED; AGED, 80 AND OVER; ERYTHROPOIETIN; FEMALE; HUMANS; INTERLEUKIN-10; INTERLEUKIN-6; MALE; MIDDLE AGED; POLYMORPHISM, GENETIC; RENAL DIALYSIS;

EID: 36749075732     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfm244     Document Type: Article

References (28)

1. U.S.Renal Data System. USRDS 2005 Annual Data Report: Atlas of End-Stage Renal Disease in the United States. National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD.
2. Locatelli F, Andrulli S, Memoli B et al. Nutritional-inflammation status and resistance to erythropoietin therapy in haemodialysis patients. Nephrol Dial Transplant 2006; 21: 991-998
3. Stenvinkel P, Barany P. Anaemia, rHuEPO resistance, and cardiovascular disease in end-stage renal failure; links to inflammation and oxidative stress. Nephrol Dial Transplant 2002; 17 [Suppl 5]: 32-37
4. Weiss G, Goodnough LT. Anemia of chronic disease. N Engl J Med 2005; 352: 1011-1023
5. Stenvinkel P, Ketteler M, Johnson RJ et al. IL-10, IL-6, and TNF-alpha: central factors in the altered cytokine network of uremia - the good, the bad, and the ugly. Kidney Int 2005; 67: 1216-1233
6. Stenvinkel P, Wanner C, Metzger T et al. Inflammation and outcome in end-stage renal failure: does female gender constitute a survival advantage? Kidney Int 2002; 62: 1791-1798
7. Zimmermann J, Herrlinger S, Pruy A, Metzger T, Wanner C. Inflammation enhances cardiovascular risk and mortality in hemodialysis patients. Kidney Int 1999; 55: 648-658
8. Bologa RM, Levine DM, Parker TS et al. Interleukin-6 predicts hypoalbuminemia, hypocholesterolemia, and mortality in hemodialysis patients. Am J Kidney Dis 1998; 32: 107-114
9. Girndt M, Sester U, Kaul H, Köhler H. Production of proinflammatory and regulatory monokines in hemodialysis patients shown at a single cell level. J Am Soc Nephrol 1998; 9: 1689-1696
10. Hsu PY, Lin CL, Yu CC et al. Ultrapure dialysate improves iron utilization and erythropoietin response in chronic hemodialysis patients - a prospective cross-over study. J Nephrol 2004; 17: 693-700
11. Girndt M, Sester U, Sester M et al. The interleukin-10 promotor genotype determines clinical immune function in hemodialysis patients. Kidney Int 2001; 60: 2385-2391
12. Girndt M, Kaul H, Sester U et al. Anti-inflammatory interleukin-10 genotype protects dialysis patients from cardiovascular events. Kidney Int 2002; 62: 949-955
13. Locatelli F, Aljama P, Barany P et al. Revised European best practice guidelines for the management of anaemia in patients with chronic renal failure. Nephrol Dial Transplant 2004; 19 [Suppl 2]: 1-47
14. Schluter B, Raufhake C, Erren M et al. Effect of the interleukin-6 promoter polymorphism (-174 G/C) on the incidence and outcome of sepsis. Crit Care Med 2002; 30: 32-37
15. Perrey C, Turner SJ, Pravica V, Howell WM, Hutchinson IV. ARMS-PCR methodologies to determine IL-10, TNF-alpha, TNF-beta and TGF-beta 1 gene polymorphisms. Transpl Immunol 1999; 7: 127-128
16. Nordfors L, Jansson M, Sandberg G et al. Large-scale genotyping of single nucleotide polymorphisms by Pyrosequencing TM and validation against the 5′nuclease (Taqman((R))) assay. Hum Mutat 2002; 19: 395-401
17. Fishman D, Faulds G, Jeffery R et al. The effect of novel polymorphisms in the interleukin-6 (IL-6) gene on IL-6 transcription and plasma IL-6 levels, and an association with systemic-onset juvenile chronic arthritis. J Clin Invest 1998; 102: 1369-1376
18. Liu Y, Berthier-Schaad Y, Fallin MD et al. IL-6 haplotypes, inflammation, and risk for cardiovascular disease in a multi-ethnic dialysis cohort. J Am Soc Nephrol 2006; 17: 863-870
19. Sharples EJ, Varagunam M, Sinnott PJ, McCloskey DJ, Raftery MJ, Yaqoob MM. The effect of proinflammatory cytokine gene and angiotensin-converting enzyme polymorphisms on erythropoietin requirements in patients on continuous ambulatory peritoneal dialysis. Perit Dial Int 2006; 26: 64-68
20. Honda H, Qureshi AR, Heimburger O et al. Serum albumin, C-reactive protein, interleukin 6, and fetuin a as predictors of malnutrition, cardiovascular disease, and mortality in patients with ESRD. Am J Kidney Dis 2006; 47: 139-148
21. Barany P, Divino-Filho JC, Bergstrom J. High C-reactive protein is a strong predictor of resistance to erythropoietin in hemodialysis patients. Am J Kidney Dis 1997; 29: 565-568
22. Gunnell J, Yeun JY, Depner TA, Kaysen GA. Acute-phase response predicts erythropoietin resistance in hemodialysis and peritoneal dialysis patients. Am J Kidney Dis 1999; 33: 63-72
23. Stenvinkel P, Heimbürger O, Paultre F et al. Strong association between malnutrition, inflammation, and atherosclerosis in chronic renal failure. Kidney Int 1999; 55: 1899-1911
24. Kalantar-Zadeh K, McAllister CJ, Lehn RS, Lee GH, Nissenson AR, Kopple JD. Effect of malnutrition-inflammation complex syndrome on EPO hyporesponsiveness in maintenance hemodialysis patients. Am J Kidney Dis 2003; 42: 761-773
25. Goicoechea M, Martin J, de-Sequera P et al. Role of cytokines in the response to erythropoietin in hemodialysis patients. Kidney Int 1998; 54: 1337-1343
26. Nemeth E, Rivera S, Gabayan V et al. IL-6 mediates hypoferremia of inflammation by inducing the synthesis of the iron regulatory hormone hepcidin. J Clin Invest 2004; 113: 1271-1276
27. Fiorentino DF, Zlotnik A, Mosmann TR, Howard M, O'Garra A. IL-10 inhibits cytokine production by activated macrophages. J Immunol 1991; 147: 3815-3822
28. Tilg H, Ulmer H, Kaser A, Weiss G. Role of IL-10 for induction of anemia during inflammation. J Immunol 2002; 169: 2204-2209